SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, +59

Cell

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Aekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, +27

Cell

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Brian J. Willett, Joe Grove, Oscar A. MacLean, +683

Nature Microbiology

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Rebecca Payne, Stephanie Longet, James Austin, +132

Cell

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

John Frater, Katie Ewer, Ane Ogbe, +66

The Lancet HIV

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Rungtiwa Nutalai, Daming Zhou, Aekkachai Tuekprakhon, +32

Cell

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Donal Skelly, Adam Harding, Javier Gilbert‐Jaramillo, +53

Nature Communications

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Adrienn Angyal, Stéphanie Longet, Shona C. Moore, +176

The Lancet Microbe

VaccinologyVaccinationImmunologyVaccine TrialCd4 T Cell Responses +4

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, +77

Nature Medicine

COVID-19 Mortality and Progress Toward Vaccinating Older Adults — World Health Organization, Worldwide, 2020–2022

Man Kai Wong, Donald Brooks, Juniorcaius Ikejezie, +44

MMWR Morbidity and Mortality Weekly Report